Trial Profile
An open-label, non-randomized, pilot study investigating effect on bone mineral density and bone turnover markers in HIV patients shifting from tenofovir to raltegravir therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Oct 2015
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Tenofovir
- Indications HIV-1 infections
- Focus Pharmacodynamics; Therapeutic Use
- 22 Oct 2015 New trial record